BioWorld

Sep. 26, 2006

GPC Biotech Shares Jump On Prostate Cancer Study Results

House Committee Passes Bill For Biodefense Agency

NovaCardia Series B Raises $48M For Phase III CHF Bid

Other News To Note

Clinic Roundup

Fampridine-SR Data Sends Acorda Stock Through Roof

Shares in Acorda Therapeutics Inc. rocketed by more than 282 percent Monday on positive findings from a Phase III study of Fampridine-SR in multiple sclerosis. (BioWorld Today) Read More

BIO Midwest Event Brings Biotech, VCs To Cleveland

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...